| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Pathology, The Northwestern University Medical School, Chicago, Illinois 60611 [J. K. R., M. S. R.]; The Clinical Pharmacology and Toxicology Center, The University of Kansas Medical Center, Kansas City, Kansas 66103 [D. L. A.]; and Department of Pathology, The University of California School of Medicine, San Diego, California 92037 [S. S.]
Long-term effects of Wy-14,643 ([4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid), a potent hepatic peroxisome proliferator structurally unrelated to the clinically used drug clofibrate, were investigated in male acatalasemic CSb mice and F344 rats. Acatalasemic mice were fed Wy-14,643 at a dietary concentration of 0.1% (w/w) for 6 months and then at 0.05% (w/w) until the termination of the experiment at 14.5 months. F344 rats were fed this compound at a 0.1% (w/w) level in the diet for 16 months. Hepatocellular carcinomas developed in 18 of 18 acatalasemic mice and 15 of 15 F344 rats that survived chronic Wy-14,643 treatment. Metastases to lungs were observed in 5 of 18 mice and 6 of 15 rats with Wy-14,643-induced hepatocellular carcinomas. The primary liver tumors in rats contained numerous peroxisomes. The increase in the number of these organelles in tumor cells was associated with a significant elevation of carnitine acetyltransferase activity, suggesting that these intrahepatic tumors respond to the peroxisome proliferative effect of Wy-14,643. The catalase activity of these tumors, however, was not increased.
Short-term administration of Wy-14,643 induced DNA replication and cell division in the rat liver as determined by [3H]thymidine incorporation into DNA, autoradiography, and colchicine-arrested metaphases in liver cells. The stimulation of liver cell proliferation was not associated with hepatocellular necrosis. The elevations of serum 
-fetoprotein concentration were associated with and proportional to liver cell proliferation.
The observation that nafenopin and Wy-14,643, 2 structurally unrelated hypolipidemic agents, induce "primary" liver cell proliferation and hepatocellular carcinomas prompts a concern over the potential carcinogenicity of hepatic peroxisome proliferators as a class.
1 Supported by NIH Research Grant GM-23750.
2 To whom requests for reprints should be addressed, at Department of Pathology, The Medical School, Ward Memorial Building, Northwestern University, 303 East Chicago Avenue, Chicago, Ill. 60611.
3 Present address: G. D. Searle & Co., P. O. Box 5110, Chicago, Ill. 60680.
Received 8/ 4/78. Accepted 10/ 6/78.
This article has been cited by other articles:
|
|
 |
|
  Y. Zhen, K. W. Krausz, C. Chen, J. R. Idle, and F. J. Gonzalez Metabolomic and Genetic Analysis of Biomarkers for Peroxisome Proliferator-Activated Receptor {alpha} Expression and Activation Mol. Endocrinol., September 1, 2007; 21(9): 2136 - 2151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. Woods, A. M. Burns, B. U. Bradford, P. K. Ross, O. Kosyk, J. A. Swenberg, M. L. Cunningham, and I. Rusyn WY-14,643 Induced Cell Proliferation and Oxidative Stress in Mouse Liver are Independent of NADPH Oxidase Toxicol. Sci., August 1, 2007; 98(2): 366 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Morimura, C. Cheung, J. M. Ward, J. K. Reddy, and F. J. Gonzalez Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor {alpha} to Wy-14,643-induced liver tumorigenesis Carcinogenesis, May 1, 2006; 27(5): 1074 - 1080. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Jia, C. Qi, P. Kashireddi, S. Surapureddi, Y.-J. Zhu, M. S. Rao, D. Le Roith, P. Chambon, F. J. Gonzalez, and J. K. Reddy Transcription Coactivator PBP, the Peroxisome Proliferator-activated Receptor (PPAR)-binding Protein, Is Required for PPAR{alpha}-regulated Gene Expression in Liver J. Biol. Chem., June 4, 2004; 279(23): 24427 - 24434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Reddy Peroxisome Proliferators and Peroxisome Proliferator-Activated Receptor {alpha}: Biotic and Xenobiotic Sensing Am. J. Pathol., June 1, 2004; 164(6): 2305 - 2321. [Full Text] [PDF]
|
|
|
|
|
|
T. C. Weglarz and E. P. Sandgren Cell cross-talk mediates PPAR{alpha} null hepatocyte proliferation after peroxisome proliferator exposure Carcinogenesis, January 1, 2004; 25(1): 107 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Yadetie, A. Laegreid, I. Bakke, W. Kusnierczyk, J. Komorowski, H. L. Waldum, and A. K. Sandvik Liver gene expression in rats in response to the peroxisome proliferator-activated receptor-{alpha} agonist ciprofibrate Physiol Genomics, September 29, 2003; 15(1): 9 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Jessen, J. S. Mullins, A. de Peyster, and G. J. Stevens Assessment of Hepatocytes and Liver Slices as in Vitro Test Systems to Predict in Vivo Gene Expression Toxicol. Sci., September 1, 2003; 75(1): 208 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Iida, C. H. Anna, J. Hartis, M. Bruno, B. Wetmore, J. R. Dubin, S. Sieber, L. Bennett, M. L. Cunningham, R. S. Paules, et al. Changes in global gene and protein expression during early mouse liver carcinogenesis induced by non-genotoxic model carcinogens oxazepam and Wyeth-14,643 Carcinogenesis, April 1, 2003; 24(4): 757 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. D. Sistare, K. L. Thompson, R. Honchel, and J. DeGeorge Evaluation of the Tg.AC Transgenic Mouse Assay for Testing the Human Carcinogenic Potential of Pharmaceuticals--Practical Pointers, Mechanistic Clues, and New Questions International Journal of Toxicology, January 1, 2002; 21(1): 65 - 79. [Abstract] [PDF]
|
|
|
|
|
|
J. S. Isenberg, L. M. Kamendulis, D. C. Ackley, J. H. Smith, G. Pugh Jr., A. W. Lington, R. H. McKee, and J. E. Klaunig Reversibility and Persistence of Di-2-ethylhexyl Phthalate (DEHP)- and Phenobarbital-Induced Hepatocellular Changes in Rodents Toxicol. Sci., December 1, 2001; 64(2): 192 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yu, W.-Q. Cao, P. Kashireddy, K. Meyer, Y. Jia, D. E. Hughes, Y. Tan, J. Feng, A. V. Yeldandi, M. S. Rao, et al. Human Peroxisome Proliferator-activated Receptor alpha (PPARalpha ) Supports the Induction of Peroxisome Proliferation in PPARalpha -deficient Mouse Liver J. Biol. Chem., November 2, 2001; 276(45): 42485 - 42491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Tharappel, M. L. Cunningham, B. T. Spear, and H. P. Glauert Differential Activation of Hepatic NF-{{kappa}}B in Rats and Hamsters by the Peroxisome Proliferators Wy-14,643, Gemfibrozil, and Dibutyl Phthalate Toxicol. Sci., July 1, 2001; 62(1): 20 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kiss, R. Ortiz-Aguayo, R. Sharp, G. Merlino, S. S. Thorgeirsson, F. J. Gonzalez, and J. M. Peters Evidence that reduction of hepatocyte growth factor (HGF) is not required for peroxisome proliferator-induced hepatocyte proliferation Carcinogenesis, June 1, 2001; 22(6): 975 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Lawrence, G. K. Wollenberg, and J. G. DeLuca Tumor necrosis factor {{alpha}} is not required for WY14,643-induced cell proliferation Carcinogenesis, March 1, 2001; 22(3): 381 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Nicholls-Grzemski, I. C. Calder, B. G. Priestly, and P. C. Burcham Clofibrate-Induced in Vitro Hepatoprotection against Acetaminophen Is Not Due to Altered Glutathione Homeostasis Toxicol. Sci., July 1, 2000; 56(1): 220 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ashby, A. Brady, C.R. Elcombe, B.M. Elliott, J. Ishmael, J. Odum, J.D. Tugwood, S. Kettle, and I.F.H. Purchase Mechanistically-based Human Hazard Assessment of Peroxisome Proliferator-induced Hepatocarcinogenesis Human and Experimental Toxicology, January 1, 1994; 13(2_suppl): S1 - S117. [PDF]
|
|
|
|
 |
|
 A. M. Bendele, J. F. Hulman, S. White, C. Brodhecker, and R. A. Bendele Hepatocellular Proliferation in Ibuprofen-Treated Mice Toxicol Pathol, January 1, 1993; 21(1): 15 - 20. [Abstract] [PDF]
|
|
|
|
|
|
S. Green Receptor-Mediated Non-Genotoxic Carcinogenesis: New Models for Risk Assessment? Human and Experimental Toxicology, January 1, 1991; 10(6): 390 - 395. [PDF]
|
|
|
|
 |
|
 B. E. Butterworth, D. J. Loury, T. Smith-Oliver, and R. C. Cattley The Potential Role of Chemically Induced Hyperplasia in the Carcinogenic Activity of the Hypolipidemic Carcinogens Toxicology and Industrial Health, January 1, 1987; 3(2): 129 - 149. [Abstract] [PDF]
|
|
|
|
|
|
J. K. Reddy, D. G. Scarpelli, V. Subbarao, and N. D. Lalwani Chemical Carcinogens Without Mutagenic Activity: Peroxisome Proliferators As A Prototype Toxicol Pathol, February 1, 1983; 11(2): 172 - 180. [Abstract] [PDF]
|
|
|
|
|
|
N. D. Lalwani, M. Kumudavalli Reddy, S. A. Qureshi, C. R. Sirtori, Y. Abiko, and J. K. Reddy Evaluation of Selected Hypolipidemic Agents for the Induction of Peroxisomal Enzymes and Peroxisome Proliferation in the Rat Liver Human and Experimental Toxicology, January 1, 1983; 2(1): 27 - 48. [Abstract] [PDF]
|
|
|
|
|
|
M.K. Reddy, N.D. Lalwani, S.A. Qureshi, and J.K. Reddy Induction of Hamster Hepatic Peroxisomal {beta}-oxidation and Peroxisome Proliferation-associated 80000 mol. wt. Polypeptide by Hypolipidemic Drugs Human and Experimental Toxicology, March 1, 1982; 1(2): 135 - 147. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
